Carmel Capital Management L.L.C. Lowers Holdings in Johnson & Johnson (NYSE:JNJ)

Carmel Capital Management L.L.C. trimmed its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 3.1% during the 2nd quarter, Holdings Channel.com reports. The fund owned 3,950 shares of the company’s stock after selling 125 shares during the period. Carmel Capital Management L.L.C.’s holdings in Johnson & Johnson were worth $701,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Family CFO Inc purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $26,000. RE Dickinson Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after buying an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC lifted its position in shares of Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after buying an additional 120 shares in the last quarter. Professional Financial Advisors LLC lifted its position in shares of Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares in the last quarter. Finally, Joseph P. Lucia & Associates LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth about $38,000. 68.59% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.5 %

JNJ opened at $167.60 on Monday. The stock has a market cap of $440.65 billion, a price-to-earnings ratio of 24.40, a P/E/G ratio of 2.99 and a beta of 0.61. The stock’s 50 day moving average price is $168.96 and its 200-day moving average price is $174.29. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. Johnson & Johnson’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.48 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 10.7 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a $1.13 dividend. The ex-dividend date was Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.70%. Johnson & Johnson’s payout ratio is 65.79%.

Johnson & Johnson announced that its Board of Directors has initiated a share repurchase plan on Wednesday, September 14th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to buy up to 1.2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on JNJ shares. Morgan Stanley decreased their target price on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Monday, September 12th. UBS Group reduced their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. SVB Leerink reduced their price objective on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Finally, Citigroup reduced their price objective on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.78.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.